Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report issued on Sunday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

Shares of AXDX stock opened at $1.15 on Friday. The stock has a market cap of $28.68 million, a P/E ratio of -0.40 and a beta of 0.55. The company has a fifty day moving average price of $1.18 and a two-hundred day moving average price of $1.49. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $2.09.

Hedge Funds Weigh In On Accelerate Diagnostics

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in Accelerate Diagnostics in the 4th quarter valued at about $27,000. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics during the 3rd quarter worth approximately $34,000. Renaissance Technologies LLC boosted its position in Accelerate Diagnostics by 160.6% during the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after buying an additional 65,984 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Accelerate Diagnostics by 6.9% in the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock worth $163,000 after purchasing an additional 8,777 shares during the period. 17.14% of the stock is owned by institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.